Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies

Clinical Pharmacokinetics

Volumn 56, Issue 2, 2017, Pages 127-138

  Marsot, Amélie ^a   Guilhaumou, Romain ^a   Riff, Camille ^a   Blin, Olivier ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT;

BLOOD SAMPLING; BODY WEIGHT; COMPARTMENT MODEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; ELIMINATION RATE CONSTANT; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; PERIPHERAL VOLUME OF DISTRIBUTION; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; STRUCTURAL MODEL; VOLUME OF DISTRIBUTION; CLINICAL TRIAL (TOPIC); CRITICAL ILLNESS; FEMALE; MALE; META ANALYSIS; PROCEDURES;

AMIKACIN; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; FEMALE; HUMANS; MALE;

EID: 84975225033     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0428-x     Document Type: Review

References (45)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228. doi:10.1007/s00134-012-2769-8 [Epub 2013 Jan 30].
2. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis. 2004;4(8):519–27.
3. Begg EJ, Barclay ML. Aminoglycosides—50 years on. Br J Clin Pharmacol. 1995;39:597–603.
4. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93–9.
5. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. Principles of therapeutic drug monitoring, 3rd ed. Vancouver: Applied Therapeutics; 1992;14:1–47.
6. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755–73.
7. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–34.
8. Paepe De, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41:1135–51.
9. Power BM, Forbes AM, van Heerden PV, Ilet KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet. 1998;34:25–56.
10. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 2004;30:2145–56.
11. Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet. 1988;14:347–73.
12. Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojenska A, Kubler A. Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013;17:R165.
13. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27–36. doi:10.1111/j.1365-2125.2011.04080.x.
14. Wong G, Sime FB, Lipman J, Roberts JA. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis. 2014;28(14):288. doi:10.1186/1471-2334-14-288 (Review).
15. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411–59.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):1–6.
17. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F. Are population pharmacokinetics and/or pharmacodynamic model adequately evaluated? A survey of the littérature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221–34.
18. Tod M, Jullien V, Pons G. facilitation of drug evaluation in children by population methods and modeling. Clin Pharmacokinet. 2008;47(4):231–43.
19. Burdet C, Pajot O, Couffignal C, Armand-Lefevre L, Foucrier A, Laouenan C, Wolff M, Massias L, Mentre F. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71:75–83.
20. Matar MK, Al-lanqawi Y, Abdul-Malek K, Jelliffe R. Amikacin population pharmacokinetics in critically ill Kuwaiti patients. Biomed Res Int. 2013;2013:202818. doi:10.1155/2013/202818 Epub 2013 Jan 30.
21. Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit. 2010;32:749–56.
22. Romano S, De Catta M, Calvo V, Mendez E, Dominguez-Gil A, Lanao JM. Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients. Clin Drug Invest. 1998;15(5):435–44.
23. Joubert P, Bressolle F, Gouby A, Doucot PY, Saissi G, Gomeni R. A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen. Eur J Drug Metab Pharmacokinet. 1999;24(1):39–46.
24. Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, Gomeni R. Population pharmacokinetics of amikacin in critically ill patients. AAC. 1996;40(7):1682–9.
25. Debord J, Pessis C, Voultoury JC, Marquet P, Lotfi H, Merle L, Lachatre G. Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm. Fundam Clin Pharmacol. 1995;9:57–61.
26. Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med. 1997;25(5):806–11.
27. Jang SB, Lee YJ, Park MS, Song YG, Kim JH, Kim HK, Ahn BS, Park K. Population pharmacokinetics of amikacin in a Korean clinical population. Int J Clin Pharmacol Ther. 2011;49(6):371–81.
28. Lugo G, Castaneda-Hernandez G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit. 1997;19:271–6.
29. Garraffo R, Drugeon HB, Dellamonica P, Bernard E, Lapalus P. Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother. 1990;34(4):614–21.
30. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53.
31. van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis. 2001;1(3):165–74 (Review).
32. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9. doi:10.1001/jama.2009.1754.
33. Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet. 2011;50(11):689–704. doi:10.2165/11592900-000000000-00000 (Review).
34. Boselli E, Breilh D, Rimmelé T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30(5):989–91 Epub 2004 Feb 24.
35. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2011;55(4):1606–10. doi:10.1128/AAC.01330-10 Epub 2011 Feb 7.
36. Regeur L, Colding H, Jensen H, Kampmann JP. Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. AAC. 1997;11(2):214–8.
37. Zaske DE, Strate RG, Kohls PR. Amikacin pharmacokinetics: wide interpatient variation in 98 patients. J Clin Pharmacol. 1991;31(2):158–63.
38. Mathews A, Bailie GR. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. J Clin Pharm Ther. 1987;12(5):273–91.
39. Van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 1990;16(3):S235–8.
40. Oparaoji EC, Cornwell EE 3rd, Hekmat E, Lum Cheong R, Adir JS, Siram S. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm. 1993;12(2):131–4.
41. Berry AJ. Respiratory support and renal function. Anesthesiology. 1981;55:655–67.
42. Richard C, Berdeaux A, Delion F, Riou B, Rimailho A, Giudicelli JF, Auzépy P. Effect of mechanical ventilation on hepatic drugs pharmacokinetics. Chest. 1986;90:837–41.
43. Triginer C, Izquierdo I, Fernández R, Rello J, Torrent J, Benito S, Net A. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990;16:303–6.
44. Dasta JF, Amstrong DK. Variability in aminoglucoside pharmacokinetics in critically ill surgical patients. Crit Care Med. 1988;16:327–30.
45. Watling SM, Dasta JF. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother. 1993;27:351–7.